🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating globally, with data suggesting in excess of 82 million instances annually. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This approval marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Global Access

As per results detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which involves an injection and a pill. The study included over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians directly involved have expressed positive views. The availability of a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.